| Literature DB >> 35211555 |
Xian-Dong Feng1, Xue Xie1, Rui He1, Fang Li1, Gui-Zhong Tang2.
Abstract
BACKGROUND: Secondary hyperparathyroidism, renal osteodystrophy, and cardiovascular adverse events can occur if long-term hyperphosphatemia is not corrected, leading to the adverse prognosis of patients with chronic renal failure. Besides the use of phosphorus binders, clinical control measures for hyperphosphatemia in these patients should also incorporate diet control. AIM: To observe doctor-led intensive diet education effects on health-related quality of life in patients with chronic renal failure and hyperphosphatemia.Entities:
Keywords: Chronic renal failure; Dietary education; Hemodialysis; Hyperphosphatemia; Quality of life; Satisfaction
Year: 2022 PMID: 35211555 PMCID: PMC8855186 DOI: 10.12998/wjcc.v10.i4.1217
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
General data comparison between patient groups
|
|
|
|
| Male/female | 35/25 | 33/27 |
| Age (yr) | 60.14 ± 8.23 | 59.96 ± 8.17 |
| Dialysis time (mo) | 12.86 ± 2.11 | 12.78 ± 2.53 |
| Dialysis frequency (sub/w) | 2.81 ± 0.56 | 2.78 ± 0.61 |
| Dialysis duration (h/w) | 10.52 ± 2.12 | 10.48 ± 2.25 |
| Cause of renal failure (glomerulonephritis/hypertension/diabetes/others) | 24/16/14/6 | 25/13/15/7 |
| Education background (Junior and below/High and Junior/undergraduate and above) | 12/35/13 | 10/34/16 |
| Marriage status (Unwed/married/divorced) | 6/47/7 | 9/46/5 |
| Fee payment method (Medical care/Rural cooperative care/self-funded) | 43/13/4 | 38/17/5 |
Comparison of blood parathyroid hormone, calcium, phosphorus, and calcium-phosphorus product levels between the two groups (mean ± SD)
|
|
|
|
|
|
|
|
| Control group | 60 | Before the intervention | 379.63 ± 43.25 | 2.30 ± 0.25 | 2.15 ± 0.36 | 4.82 ± 0.69 |
| Intervention for 3 mo | 312.36 ± 36.21 | 2.19 ± 0.22 | 2.02 ± 0.29 | 4.61 ± 0.56 | ||
| Intervention for 6 mo | 295.69 ± 21.44 | 2.11 ± 0.26 | 2.05 ± 0.25 | 4.55 ± 0.56 | ||
| Observation group | 60 | Before the intervention | 383.45 ± 42.96 | 2.28 ± 0.26 | 2.19 ± 0.33 | 1.78 ± 0.78 |
| Intervention for 3 mo | 296.88 ± 28.02 | 2.11 ± 0.21 | 1.73 ± 0.31 | 4.15 ± 0.46 | ||
| Intervention for 6 mo | 249.63 ± 23.44 | 2.08 ± 0.26 | 1.70 ± 0.26 | 4.08 ± 0.49 |
P < 0.05 vs those before intervention in this group.
P < 0.05 vs the control group.
iPTH: Serum parathyroid hormone; Ca: Calcium; P: Phosphorus; Ca × P calcium-phosphorus product.
Comparison of renal function indicators between the two groups (mean ± SD)
|
|
|
|
|
|
| Control group | 60 | Before the intervention | 1120.36 ± 241.36 | 36.85 ± 10.52 |
| Intervention for 3 mo | 1055.89 ± 269.33 | 35.84 ± 9.88 | ||
| Intervention for 6 mo | 1078.96 ± 271.54 | 37.11 ± 12.45 | ||
| Observation group | 60 | Before the intervention | 1098.36 ± 268.11 | 37.32 ± 9.25 |
| Intervention for 3 mo | 1102.42 ± 301.02 | 40.02 ± 10.47 | ||
| Intervention for 6 mo | 1083.67 ± 274.25 | 38.96 ± 9.02 |
P < 0.05 vs those before intervention in this group.
P < 0.05 vs the control group.
Scr: Serum creatinine; BUN: Blood urea nitrogen.
Comparison of patient satisfaction between the two groups, n (%)
|
|
|
|
|
|
|
|
| Control group | 60 | Three months | 28 (46.67) | 20 (33.33) | 12 (20.00) | 48 (80.00) |
| Six months | 34 (56.67) | 22 (36.67) | 4 (6.67) | 56 (93.33) | ||
| Observation group | 60 | Three months | 22 (36.67) | 21 (35.00) | 17 (28.33) | 43 (71.67) |
| Six months | 30 (50.00) | 24 (40.00) | 6 (10.00) | 54 (90.00) |
P < 0.05 vs the control group.
Comparison of EQ-5D-3L scores between the two groups (mean ± SD, points)
|
|
|
|
|
|
|
|
|
|
| Control group | 60 | Before the intervention | 2.03 ± 0.44 | 2.12 ± 0.51 | 1.78 ± 0.62 | 2.16 ± 0.41 | 2.03 ± 0.52 | 58.25 ± 12.03 |
| Intervention for 3 mo | 1.54 ± 0.32 | 1.43 ± 0.43 | 1.21 ± 0.32 | 1.46 ± 0.37 | 1.50 ± 0.46 | 69.36 ± 7.14 | ||
| Intervention for 6 mo | 1.56 ± 0.41 | 1.42 ± 0.32 | 1.26 ± 0.25 | 1.38 ± 0.26 | 1.44 ± 0.51 | 68.23 ± 8.27 | ||
| Observation group | 60 | Before the intervention | 2.01 ± 0.42 | 2.14 ± 0.47 | 1.75 ± 0.56 | 2.12 ± 0.43 | 2.06 ± 0.47 | 57.44 ± 12.85 |
| Intervention for 3 mo | 1.32 ± 0.25 | 1.26 ± 0.37 | 1.09 ± 0.26 | 1.24 ± 0.33 | 1.34 ± 0.39 | 75.89 ± 6.98 | ||
| Intervention for 6 mo | 1.33 ± 0.21 | 1.22 ± 0.32 | 1.05 ± 0.24 | 1.25 ± 0.29 | 1.29 ± 0.27 | 77.02 ± 8.45 |
P < 0.05 vs those before intervention in this group.
P < 0.05 vs the control group.
VAS: Visual analogue scale.
Comparison of disease-related knowledge and compliance scores between the two groups (mean ± SD, points)
|
|
|
|
|
|
|
|
| Control group | 60 | Before the intervention | 52.14 ± 6.14 | 61.14 ± 5.85 | 46.96 ± 5.25 | 58.23 ± 10.02 |
| Intervention for 3 mo | 68.96 ± 5.44 | 73.36 ± 6.02 | 68.11 ± 6.36 | 74.01 ± 6.59 | ||
| Intervention for 6 mo | 69.23 ± 6.01 | 71.45 ± 5.22 | 64.25 ± 5.23 | 72.85 ± 6.98 | ||
| Observation group | 60 | Before the intervention | 51.92 ± 8.98 | 60.88 ± 7.23 | 48.02 ± 6.32 | 57.96 ± 8.97 |
| Intervention for 3 mo | 87.12 ± 6.55 | 84.96 ± 8.02 | 82.55 ± 7.65 | 87.55 ± 7.14 | ||
| Intervention for 6 mo | 86.25 ± 7.12 | 84.98 ± 7.96 | 85.02 ± 6.44 | 86.96 ± 8.05 |
P < 0.05 vs those before intervention in this group.
P < 0.05 vs the control group.